Blher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM
A significant reduction in pro-inflammatory molecules, including C-reactive protein (CRP), TNF- , and IL-6, was observed, indicating the inhibition of inflammatory pathways, likely at the level of immune system cells and adipocytes signaling
doi: 10.1139/y69-020 9 BrownJC
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
10.1016/j.molmet.2019.09.010 45 MuraliS.AradhyamG
Blossom Inuenwi, DNP, provides personalized guidance to help patients understand how GLP-1 medications work and whether a specific approach may align with their health goals and wellness needs